128 related articles for article (PubMed ID: 36634550)
1. Lung cancer presenting with central nervous system metastasis: Clinicopathological and molecular analysis of 171 cases.
Demleitner M; Erlenbach-Wünsch K; Coras R; Erber R; Polifka I; Eyüpoğlu I; Fuchs F; Hartmann A; Agaimy A
Ann Diagn Pathol; 2023 Apr; 63():152082. PubMed ID: 36634550
[TBL] [Abstract][Full Text] [Related]
2. SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1
Agaimy A; Fuchs F; Moskalev EA; Sirbu H; Hartmann A; Haller F
Virchows Arch; 2017 Nov; 471(5):599-609. PubMed ID: 28555282
[TBL] [Abstract][Full Text] [Related]
3. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.
Herpel E; Rieker RJ; Dienemann H; Muley T; Meister M; Hartmann A; Warth A; Agaimy A
Ann Diagn Pathol; 2017 Feb; 26():47-51. PubMed ID: 28038711
[TBL] [Abstract][Full Text] [Related]
4. Correlation between molecular analysis, diagnosis according to the 2015 WHO classification of unresected lung tumours and TTF1 expression in small biopsies and cytology specimens from 344 non-small cell lung carcinoma patients.
Russell PA; Rogers TM; Solomon B; Alam N; Barnett SA; Rathi V; Williams RA; Wright GM; Conron M
Pathology; 2017 Oct; 49(6):604-610. PubMed ID: 28811082
[TBL] [Abstract][Full Text] [Related]
5. [Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].
Fang F; Wang YX; Hu ST; Yang L; Di J; Liu DG; Lyu N
Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):432-437. PubMed ID: 29886587
[No Abstract] [Full Text] [Related]
6. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
[TBL] [Abstract][Full Text] [Related]
7. High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer.
Preusser M; Berghoff AS; Berger W; Ilhan-Mutlu A; Dinhof C; Widhalm G; Dieckmann K; Wöhrer A; Hackl M; von Deimling A; Streubel B; Birner P
Lung Cancer; 2014 Jan; 83(1):83-9. PubMed ID: 24183471
[TBL] [Abstract][Full Text] [Related]
8. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
Ghosh M; Mukhopadhyay M; Das C; Chatterjee S; Naskar BG
J Cancer Res Ther; 2021; 17(6):1389-1396. PubMed ID: 34916369
[TBL] [Abstract][Full Text] [Related]
9. [Clinicopathological features of SMARCA4-deficient lung adenocarcinoma: a study of 42 cases].
Han J; Gao XZ; Xu Y; Liu EJ; Du Q; Chen K; Li SL
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):136-142. PubMed ID: 38281780
[No Abstract] [Full Text] [Related]
10. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
[TBL] [Abstract][Full Text] [Related]
11. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer.
Salido M; Pijuan L; Martínez-Avilés L; Galván AB; Cañadas I; Rovira A; Zanui M; Martínez A; Longarón R; Sole F; Serrano S; Bellosillo B; Wynes MW; Albanell J; Hirsch FR; Arriola E
J Thorac Oncol; 2011 Jan; 6(1):21-7. PubMed ID: 21107285
[TBL] [Abstract][Full Text] [Related]
12. Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma.
Zito Marino F; Liguori G; Aquino G; La Mantia E; Bosari S; Ferrero S; Rosso L; Gaudioso G; De Rosa N; Scrima M; Martucci N; La Rocca A; Normanno N; Morabito A; Rocco G; Botti G; Franco R
PLoS One; 2015; 10(9):e0139264. PubMed ID: 26422230
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
14. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis.
Tang X; Kadara H; Behrens C; Liu DD; Xiao Y; Rice D; Gazdar AF; Fujimoto J; Moran C; Varella-Garcia M; Lee JJ; Hong WK; Wistuba II
Clin Cancer Res; 2011 Apr; 17(8):2434-43. PubMed ID: 21257719
[TBL] [Abstract][Full Text] [Related]
15. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.
Zhang X; Zhang S; Yang X; Yang J; Zhou Q; Yin L; An S; Lin J; Chen S; Xie Z; Zhu M; Zhang X; Wu YL
Mol Cancer; 2010 Jul; 9():188. PubMed ID: 20624322
[TBL] [Abstract][Full Text] [Related]
16. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z
Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods.
Kao HL; Yeh YC; Lin CH; Hsu WF; Hsieh WY; Ho HL; Chou TY
Lung Cancer; 2016 Nov; 101():40-47. PubMed ID: 27794407
[TBL] [Abstract][Full Text] [Related]
18. SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant.
Cheung AH; Wong KY; Chau SL; Xie F; Mui Z; Li GY; Li MSC; Tong J; Ng CS; Mok TS; Kang W; To KF
Pathology; 2024 Jun; 56(4):504-515. PubMed ID: 38413251
[TBL] [Abstract][Full Text] [Related]
19. Perspectives and Issues in the Assessment of
Armon S; Hofman P; Ilié M
Cells; 2021 Jul; 10(8):. PubMed ID: 34440689
[TBL] [Abstract][Full Text] [Related]
20. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.
Rekhtman N; Brandt SM; Sigel CS; Friedlander MA; Riely GJ; Travis WD; Zakowski MF; Moreira AL
J Thorac Oncol; 2011 Mar; 6(3):451-8. PubMed ID: 21266922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
